Cargando…
Complication of coronavirus disease 2019 during remission induction therapy against anti-MDA5 antibody-positive dermatomyositis
Autores principales: | Kogami, Masahiro, Suzuki, Satoshi, Nanjo, Yuta, Ikeda, Keigo, Tamura, Naoto, Sasaki, Shinichi, Morimoto, Shinji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717435/ https://www.ncbi.nlm.nih.gov/pubmed/33336141 http://dx.doi.org/10.1093/rap/rkaa068 |
Ejemplares similares
-
Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis
por: Hirai, Takuya, et al.
Publicado: (2018) -
7. Anti-MDA5 associated dermatomyositis
por: Laverty, Ursula, et al.
Publicado: (2019) -
Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022) -
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023) -
Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
por: Ikeda, Satoshi, et al.
Publicado: (2015)